Description:
This study is designed to compare the anti-tumor activity as well as the safety and efficacy
of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer
subjects previously treated with trastuzumab and taxane.
Title
- Brief Title: DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- Official Title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Clinical Trial IDs
- ORG STUDY ID:
DS8201-A-U302
- SECONDARY ID:
2018-000222-61
- SECONDARY ID:
183976
- SECONDARY ID:
DESTINY-B03
- NCT ID:
NCT03529110
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Trastuzumab deruxtecan (DS-8201a) | DS-8201a | Trastuzumab deruxtecan (DS-8201a) |
Ado-trastuzumab emtansine (T-DM1) | T-DM1 | Ado-trastuzumab emtansine (T-DM1) |
Purpose
This study is designed to compare the anti-tumor activity as well as the safety and efficacy
of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer
subjects previously treated with trastuzumab and taxane.
Trial Arms
Name | Type | Description | Interventions |
---|
Trastuzumab deruxtecan (DS-8201a) | Experimental | HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a | - Trastuzumab deruxtecan (DS-8201a)
|
Ado-trastuzumab emtansine (T-DM1) | Active Comparator | HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1 | - Ado-trastuzumab emtansine (T-DM1)
|
Eligibility Criteria
Inclusion Criteria:
- Is the age of majority in their country
- Has pathologically documented breast cancer that:
1. is unresectable or metastatic
2. has confirmed HER2-positive expression as determined according to American
Society of Clinical Oncology - College of American Pathologists guidelines
evaluated at a central laboratory
3. was previously treated with trastuzumab and taxane in the advanced/metastatic
setting or progressed within 6 months after neoadjuvant or adjuvant treatment
involving a regimen including trastuzumab and taxane
- Has documented radiologic progression (during or after most recent treatment or within
6 months after completing adjuvant therapy)
- Is HER2 positive as confirmed by central laboratory assessment of most recent tumor
tissue sample available. If archived tissue is not available, agrees to provide a
fresh biopsy.
- If of reproductive/childbearing potential, agrees to use a highly effective form of
contraception or avoid intercourse during and upon completion of the study for 7
months after the last dose of DS-8201a (females); 4.5 months after last dose of
DS-8201a (males) or 7 months after the last dose of T-DM1
- Has adequate renal and hepatic function
Exclusion Criteria:
- Has previously been treated with an anti-HER2 antibody drug conjugate (ADC) in the
metastatic setting. Prior treatment in the adjuvant/neo-adjuvant setting would be
allowed if progression of disease did not occur within 12 months of end of adjuvant
therapy
- Has uncontrolled or significant cardiovascular disease
- Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that
required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis
cannot be ruled out by imaging at screening
- Has spinal cord compression or clinically active central nervous system (CNS)
metastases, defined as untreated and symptomatic, or requiring therapy with
corticosteroids or anticonvulsants to control associated symptoms.
1. Participants with clinically inactive brain metastases may be included in the
study.
2. Participants with treated brain metastases that are no longer symptomatic and who
require no treatment with corticosteroids or anticonvulsants may be included in
the study if they have recovered from the acute toxic effect of radiotherapy. A
minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy
and study enrollment.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Progression-free survival (PFS) based on blinded independent central review (BICR) |
Time Frame: | Baseline up to 43 months postdose |
Safety Issue: | |
Description: | Time from the date of randomization to the earliest date of the first objective documentation of radiographic disease progression via BICR according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 or death due to any cause |
Secondary Outcome Measures
Measure: | Overall survival (OS) |
Time Frame: | Baseline up to 59 months postdose |
Safety Issue: | |
Description: | Time from the date of randomization to the date of death for any cause. If there is no death reported for a participant before the data cutoff for OS analysis, OS will be censored at the last contact date at which the participant is known to be alive. |
Measure: | Objective response rate (ORR) based on BICR and investigator's assessment |
Time Frame: | Baseline up to 59 months postdose |
Safety Issue: | |
Description: | Percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR), based on BICR and based on investigator assessment |
Measure: | Duration of response (DoR) based on BICR and investigator's assessment |
Time Frame: | Baseline up to 59 months postdose |
Safety Issue: | |
Description: | Length of time response continued, based on BICR and investigator's assessment |
Measure: | Progression-free survival (PFS) based on investigator's assessment |
Time Frame: | Baseline up to 43 months postdose |
Safety Issue: | |
Description: | Time from the date of randomization to the first objective documentation of radiographic disease progression via investigator assessment, according to mRECIST version 1.1 or death due to any cause |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Daiichi Sankyo, Inc. |
Trial Keywords
- Breast Cancer
- Metastatic breast cancer
- DS-8201a
- DESTINY - Breast 03
Last Updated
December 4, 2020